Concerning a new pathogenetic hypothesis of the E.P.H. gestosis (note II).
In this second note, the Authors report a new therapeutic protocol, based on the aetiopathogenesis, of the E.P.H. gestosis, which allows an efficient clinical control of this disease, avoiding its evolution to eclampsia.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D004461:Eclampsia / Q000188:drug therapy; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D010952:Plasma Substitutes / Q000627:therapeutic use; D011225:Pre-Eclampsia / Q000188:drug therapy* / Q000209:etiology; D011247:Pregnancy; D011507:Proteinuria / Q000188:drug therapy
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D006063:Chorionic Gonadotropin; D005338:Fibrin Fibrinogen Degradation Products; D010952:Plasma Substitutes; D006493:Heparin